Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q2 2016 · 10-Q
Revenue—
Net Income-$1.45M-$1.45MN/M vs Q2 2015 EPS Diluted-$0.01-$0.01N/M vs Q2 2015 Operating Income-$2,065,241N/M Operating Cash Flowderived-$603,173N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
ended Jun 30, 2016 · filed Aug 12, 2016 · 43 d after period end